New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation

Annals of the Rheumatic Diseases

Volumn 56, Issue 1, 1997, Pages 5-11

  Shoenfeld, Yehuda ^a,b   Krause, Ilan ^a   Blank, Miri ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; ANTIESTROGEN; BROMOCRIPTINE; CD4 ANTIBODY; CYTOKINE; DANAZOL; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; TAMOXIFEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL MODEL; CONTROLLED STUDY; HORMONAL THERAPY; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0031029474     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.56.1.5     Document Type: Review

References (71)

1. Pickering G, Bywaters EGL, Damielli JF, Gell PG, Kellgren JH. Treatment of systemic lupus erythematosus with steroids. Report to the Medical research Council by the Collagen Diseases and Hypersensitivity Panel. BMJ 1961;ii:915-20.
2. Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF. A multi center study of outcome of systemic lupus erythematosus. I. Entry variables as predictors of progress. Arthritis Rheum 1982;25:601-11.
3. Theofilopoulus AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985;37:269-90.
4. Gutierrez-Ramos JC, Andreu JL, Moreno De Alboran I. Insights into autoimmunity: from classical models to current perspectives. Immunol Rev 1990;118:73-101.
5. Portanova JP, Ebling FM, Hammond WS, Hahn BH, Kotzin BL. Allogeneic MHC antigen requirements for lupus-like autoantibody production and nephritis in murine graft-vs-host disease. J Immunol 1988; 141:3370-6.
6. Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y. Induction of primary anti-phospholipid syndrome in mice by immunization with human monoclonal anti-cardiolipin antibody (H-3). J Clin Invest 1992; 89:1558-63.
7. Blank M, Tomer Y, Stein M, Kopolovic J, Wiik A, Meroni PL, et al. Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration. Clin Exp Immunol 1995;102:120-30.
8. Shoenfeld Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 1994;8:1296-301.
9. Mendlovic S, Brocke S, Fricke H, Shoenfeld Y, Bakimer R, Mozes E. The genetic regulation of the induction of experimental SLE. Immunology 1990;69:228-36.
10. Jerne NK. Toward a network theory of the immune system. Ann Immunol 1974;125:373-89.
11. Jerne NK, Roland J, Cazenava PA. Recurrent idiotypes and internal images. EMBO J 1982;1:243-7.
12. Mendlovic S, Brocke S, Shoenfeld Y, Ben-Bassat M, Meshorer A, Bakimer R, et al. Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci USA 1988;85:2260-4.
13. Blank M, Mendelovic S, Mozes E, Shoenfeld Y. Induction of SLE like disease in naive mice with a monoclonal anti-DNA antibody derived from a parient with polymyositis carrying 16/6 Id. J Autoimmunity 1988;1:683-9.
14. Tincani A, Balesterieri G, Allegri F, Cattaneo R, Fornasieri A, Sinico A, et al. Induction of experimental SLE in naive mice by immunization with human polyclonal anti-DNA antibody carrying the 16/6 idiotype. Clin Exp Rheumatol 1994;11:129-34.
15. Blank M, Krup M, Mendelovic S, Ericke H, Mozes E, Talal N, et al. The importance of the pathogenic 16/6 idiotype in the induction of SLE in naive mice. Scand J Immunol 1990;31:45-52.
16. Shoenfeld Y, Mozes E. Pathogenic idiotypes of antibodies and autoimmunity: lessons from new experimental models of SLE. FASEB J 1990;4:2646-51.
17. Rombach E, Stetler DA, Brown JC. Rabbits produce SLE-like anti-RNA polymerase I and anti-DNA autoantibodies in response to immunization with either human or murine SLE anti-DNA antibodies. Autoimmunity 1992; 13:291-302.
18. Sela O, El-Roeiy A, Isenberg DA, Kennedy RL, Colaco CB, Pinkhas J, et al. A common anti-DNA antibody idiotype in sera of patients with active pulmonary tuberculosis. Arthritis Rheum 1987;30:50-5.
19. El-Roeiy A, Sela O, Isenberg DA, Kennedy RL, Shoenfeld Y. The sera of patients with klebsiella infections contain a common anti-DNA idiotype (16/6 Id) anti-polynucleotide activity. Clin Exp Immunol 1987;67:507-15.
20. Rubinian JR, Talal N, Greenspan JS, Goodman JR, Siiteri PK. Effect of castration and sex hormones treatment on survival, anti-nucleic acid antibodies and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 1978; 147:1568-83.
21. Lahita RG, Kunkel HG. Treatment of systemic lupus erythematosus (SLE) with the androgen 19-nortestosterone (Nandrolone) [abstr]. Arthritis Rheum 1984; 27(suppl):S65.
22. Hazelton RA, McCruden AB, Sturrock RD, Stimson WH. Hormonal manipulation of the immune response in systemic lupus erythematosus: a drug trial of an anabolic steroid, 19-nortestosterone. Ann Rheum Dis 1983; 42:155-7.
23. Blank M, Mendlovic S, Fricke H, Mozes E, Talal N Shoenfeld Y. Sex hormone involvement in the induction of experimental systemic lupus erythematosus by a pathogenic anti-DNA idiotype in naive mice. J Rheumatol 1990;17:311-7.
24. Sthoeger ZM, Bentwich Z, Zinger H, Mozes E. The beneficial effect of the estrogen antagonist, tamoxifen, on experimental systemic lupus erythematosus. J Rheumatol 1994; 21:2231-8.
25. Chan AC, Sack K. Danazol therapy for autoimmune hemolytic anemia associated with systemic lupus erythematosus [case report]. J Rheumatol 1991;18:280-2.
26. Aranegui P, Giner P, Lopez-Gomez M, el-Amrani A, Jimenez-Alonso J. Danazol for Evans syndrome due to SLE. Drug Intell Clin Pharmacol 1990;24:641-42.
27. Buskila D, Sukenic S, Shoenfeld Y. The possible role of prolactin in autoimmunity. Am J Reprod Immunol 1991; 26:118-23.
28. Whyte A, Williams RO. Bromocriptine suppresses postpartum exacerbation of collagen-induced arthritis. Arthritis Rheum 1988;31:927-8.
29. Blank M, Krause I, Buskila D, Teitelbaum D, Kopolovic J, Afek A, et al. Bromocriptine immunomodulation of experimental SLE and primary anti-phospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol 1995;162:114-22.
30. Rabinovich CE, Schanberg LE, Kredich DW. Intravenous immunoglobulin and bromocriptine in the treatment of refractory neuropsychiatric systemic lupus erythematosus [abstr]. Arthritis Rheum 1990;33:R22.
31. McMurray RW, Weidensaul D, Allen SH, Walker SE. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 1995; 11:2084-91
32. Burdette D, Schwarts RS. Idiotypes and idiotypic networks. N Engl J Med 1987;317:219-24.
33. Aguis MA, Richmann DP. Suppression of development of experimental autoimmune myasthenia gravis with isogenic monoclonal anti idiotypic antibody. J Immunol 1986; 137:2195-8.
34. Nordling C, Holmdahl R, Klareskog L. Down of collagen arthritis after in vitro treatment with syngenic monoclonal anti-idiotypic antibody to a cross reactive idiotype on collagen II autoantibodies. Immunology 1991;72:486-92.
35. Zou SR, Whitaker JN. Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies. J Immunol 1993; 150:1629-42.
36. Mansoroi J, Von Kleist S, Mansoroi A, Grunert F. Thermostability and antitumor activity on colon cancer cell lines on monoclonal anti-CEA antibody-saporin immunotoxin. J Korean Med Sci 1992;7:128-35.
37. Blank M, Mansoroi J, Tomer Y, Mansoroi A, Kopolovic J, Charcon-Polak S, et al. Suppression of experimental systemic lupus erythematosus (SLE) with specific antiidiotypic antibody-saporin conjugate. Clin Exp Immunol 1994;98:434-41.
38. Shoenfeld Y, Isenberg DA. The mosaic of autoimmunity, the factors associated with autoimmune diseases. Amsterdam: Elsvier, 1989.
39. Koing R, Huang LY, Germain RN. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature 1992; 356:796-8.
40. Benjamin RJ, Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature 1986;320:449-51.
41. Riethmuller G, Rieber B, Kiefersauer S, Prinz J, van der Lubbe P, Meiser B, et al. From antilymphocyte serum to therapeutic monoclonal antibodies: first experiences with chimeric CD4 antibody in the treatment of autoimmune disease. Immunol Rev 1992;129:81-103.
42. Reiter C, Kakavand B, Rieber EP, Schattenkirchner M, Riethmuller G, Kruger K. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151:clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum 1991;34:525-36.
43. Blank M, Mendlovic S, Mozes E, Coates ARM, Shoenfeld Y. Induction of systemic lupus erythematosus in naive mice with T-cell lines specific for human anti-DNA antibody SA-1 (16/6 Id+) and for mouse tuberculosis antibody TB/68 (16/6 Id+). Clin Immunol Immunopathol 1991;60:471-83.
44. Tomer Y, Blank M, Shoenfeld Y. Suppression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti-CD4 monoclonal antibodies. Arthritis Rheum 1994;37:1236-44.
45. Krakauker RS, Waldmann TA, Strober WJ. Loss of suppressor T cell in adult NZB/NZW mice. J Exp Med 1976;144:663-73.
46. Raziuddin S, Nur MA, Alwabel AA. Selective loss of the CD4+ inducers of suppressor T cell subsets (ZH4+) in active systemic lupus erythematosus. J Rheumatol 1989; 16:1315-9.
47. Naiki MY, Imai T, Osawa Y. Establishement of a nucleoside-specific suppressor T cell line from SLE prone (NZB/NZW)F1 mice. J Immunol 1985;135:1080-5.
48. Ellerman KE, Powers JM, Brostoff SW. A suppressor T-lymphocyte cell line for autoimmune encephalomyelitis. Nature 1988;331:265-7.
49. Blank M, Ben-Bassat M, Shoenfeld Y. Modulation of SLE induction in naive mice by specific T cells with suppressor activity to pathogenic anti-DNA idiotype. Cell Immunol 1991;137:474-86.
50. Dweyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-16.
51. Maier WP, Gordon DS, Howard RF, Saleh MN, Miller SB, Lieberman JD, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus associated thrombocytopenia. Arthritis Rheum 1990;33:1233-39.
52. Winder A, Molad Y, Ostfeld I, Kenet G, Pinkhas J, Sidi Y. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of two cases. J Rheumatol 1993;20:495-8.
53. Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992;10:391-3.
54. Ben-Chetrit E, Putterman C, Naparstek Y. Lupus refractory pleural effusion: transient response to intravenous immunoglobulins. J Rheumatol 1991;18:1635-7.
55. Krause I, Blank M, Kopolovic J, Afek A, Goldberg I, Tomer Y, et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995; 6:1068-74.
56. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human antithyroglobulin autoantibodies. J Clin Invest 1990;85:620-25.
57. Rossi F, Jayne DR, Lockwood CM, Kazatchkine MD. Antiidiotypes against anti-neutrophil cytoplasmic antigen auto-antibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991;83:298-303.
58. Evans MJ, Suenaga R, Abdou NI. Detection and purification of antiidiotypic antibodies against anti-DNA in intravenous immune globulin. J Clin Immunol 1991;11:291-5.
59. Romagnani S. Biology of human Th1 and Th2 cells. J Clin Immunol 1995;15:121-9.
60. Mills JA. Systemic lupus erythematosus. N Engl J Med 1994;330:1871-9.
61. Goldman M, Druet P, Gleichmann E. Th2 cells in systemic lupus erythematosus: insights from allogeneic diseases and chemically induced autoimmunity. Immunol Today 1991; 12:223-7.
62. Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982;69:1388-92.
63. Wofsy D, Murphy ED, Roths JB, Dauphinee MJ, Kipper SP, Talal N. Deficient interleukin-2 activity in MRL/Mp and C57BL/6J mice bearing the 1pr gene. J Exp Med 1981; 154:1671-80.
64. Sredny B, Caspi RR, Klein A, Kalechman Y, Danziger Y, Ben-Yaakov M, et al. A new immunomodulating compound (AS101) with potential therapeutic application. Nature 1987;330:173-6.
65. Blank M, Seredni B, Albeck M, Mozes E, Shoenfeld Y. The effect of the immunomodulator agent AS101 on interleukin-2 production in systemic lupus erythematosus (SLE) induced in mice by a pathogenic anti-DNA antibody. Clin Exp Immunol 1990;79:443-7.
66. Mowat MA. The regulation of immune responses to dietary protein antigens. Immunol Today 1987;8:93.
67. Higgins PJ, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 1988;140:440-5.
68. Vives J, Parks DE, Weigle WO. Immunologic unresponsiveness after gastric administration of human gamma globulin: antigen requirements and cellular parameters. J Immunol 1980;125:1811-6.
69. Carr RI, Tilley D, Forsyth S, Etheridge P, Sadi D. Failure of oral tolerance in (NZBxNZW)F1 mice is antigen specific and appears to parallel antibody pattern in human systemic lupus erythematosus (SLE). Clin Immunol Immunopathol 1987;42:298-310.
70. Miller ML, Cowdery JS, Laskin CA, Curtin MF, Steinberg AD. Heterogeneity of oral tolerance defects in autoimmune mice. Clin Immunol Immunopathol 1984;31:231-40.
71. Weiner HL, Friedmann A, Miller A, Khoury SJ, Al-Sabbagh A, Santos L, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994;12:809-37.